Phase 2 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with primary cervical cancer or uterine cancer of any type
- People who are 18 years of age or older
- People whose cancer has not spread to distant parts of the body, based on international gynaecological cancer staging guidelines
- People who have already had surgery (such as a hysterectomy) with the goal of fully removing the cancer, with no visible cancer remaining after the operation
- People whose treatment team has recommended pelvic radiation therapy on its own, without chemotherapy given at the same time (chemotherapy given before or after radiation is acceptable)
- People who are reasonably physically functional in daily life (confirm with trial site for the specific fitness level required)
- People who are willing and able to give informed consent to participate
Who may not be able to join:
- People whose cancer has spread to distant parts of the body, based on clinical assessment or imaging
- People who are receiving chemotherapy at the same time as the study treatment
- People who have visible cancer remaining after surgery, or cancer detected on imaging or during the operation itself
- People who have a history of small bowel blockage, inflammatory bowel disease, irritable bowel syndrome, a connective tissue disorder requiring ongoing treatment, or previous radiation therapy to the pelvis
- People who have unresolved moderate or severe diarrhoea or abdominal/pelvic pain related to chemotherapy that requires medication, before radiation begins
- People whose treatment team has recommended radiation to the lymph nodes near the aorta (the large artery in the abdomen)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Christina Son, MD, University of Chicago
Phone: 773-702-6870
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The Maximum Tolerated Dose of Hypofractionated Whole Pelvic Radiation Treatment (Phase 1); Change in patient-reported acute gastrointestinal side effects after completion of hypofractionated radiation (Phase 2)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.